Frontline Ltd. FRO 深 沪
等待开盘 12-16 09:30:00 美东时间
22.63
-0.230
-1.01%
华盛通- 最 高22.905
- 今 开22.90
- 成交量 92.94万股
- 最 低 22.54
- 昨 收 22.86
- 总市值 50.46亿
- 52周最高 25.81
- 市盈率 静 10.17
- 换手率 0.42%
- 52周最低 11.67
- 委 比 -39.51%
- 总股本 2.23亿
- 历史最高 42.70
- 量 比 0.42
- 振 幅 1.60%
- 历史最低 -3.81
- 每 手 1
- 风险率 3.57%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多80多艘恐被困、30多艘恐被扣押！警惕美国扣押油轮引爆委内瑞拉出口危机
美国扣押油轮引发连锁反应，参与委内瑞拉石油贸易的船东、运营商和中介机构高度警惕，目前有超过80艘油轮在委内瑞拉水域或其附近，其中30多艘受美国制裁。
12-11 20:45
FPG推出CheckMax，助力餐饮业通过AI提升利润
Frontline Performance Group（FPG）推出一款集成AI驱动型洞察的绩效提升软件CheckMax，旨在最大化客单价，有望令餐厅利润翻倍...
12-10 15:49
Flex LNG - Appointment of CEO
HAMILTON, Bermuda, Dec. 5, 2025 /PRNewswire/ -- The Board of Flex LNG Ltd ("Flex LNG" or the "Company") (NYSE: FLNG) is pleased to announce the appointment of Mr. Marius Foss as the Chief Ex...
12-05 18:27
全球海运价格年底“逆势”飙升：关键航线原油运价暴涨467%
冲突、制裁与激增的产出正颠覆全球供应链，导致从能源到大宗矿石的海运价格在年底罕见飙升。关键航线原油日均收益今年暴涨467%，液化天然气和铁矿石等运价也翻倍增长。
12-04 21:00
Black Diamond Therapeutics Shared Topline Data From Its Phase 2 Trial Of Silevertinib In Frontline Non-small Cell Lung Cancer, And Plans For Phase 2 Trial Of Silevertinib In Newly Diagnosed Glioblastoma
Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals
12-03 20:09
美股12月收息策略：最高股息率超11%！泰森食品、惠普、英美烟草等超100家高分红股如何布局！
最高股息率超11%！泰森食品、惠普、英美烟草等超100家高分红股如何布局！投资者可在除息前布局，赚取股息！一文速览派息名单>>
12-01 14:00
Frontline declares $0.19 dividend
Frontline (FRO) declares $0.19/share quarterly dividend. Forward yield 3.05% Payable Dec. 19; for shareholders of record Dec. 19; ex-div Dec. 12. See FRO Dividend Scorecard, Yield Chart, & Dividend Gr...
11-24 22:44
Frontline’s Earnings Call Highlights Strong TCE Rates and Market Optimism
Frontline (($FRO)) has held its Q3 earnings call. Read on for the main highligh...
11-24 08:04
Frontline plc Reports Third Quarter 2025 Earnings
Frontline ( ($FRO) ) has released its Q3 earnings. Here is a breakdown of the i...
11-22 11:53
Frontline Q3 Adj. EPS $0.19 Misses $1.02 Estimate, Sales $432.654M Beat $425.186M Estimate
Frontline (NYSE:FRO) reported quarterly earnings of $0.19 per share which missed the analyst consensus estimate of $1.02 by 81.41 percent. This is a 44.12 percent decrease over earnings of $0.34 per share from the same
11-22 06:44
